BR112019005783A2 - agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos - Google Patents

agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos

Info

Publication number
BR112019005783A2
BR112019005783A2 BR112019005783A BR112019005783A BR112019005783A2 BR 112019005783 A2 BR112019005783 A2 BR 112019005783A2 BR 112019005783 A BR112019005783 A BR 112019005783A BR 112019005783 A BR112019005783 A BR 112019005783A BR 112019005783 A2 BR112019005783 A2 BR 112019005783A2
Authority
BR
Brazil
Prior art keywords
binding agents
drug conjugates
monoclonal binding
cmet
cmet monoclonal
Prior art date
Application number
BR112019005783A
Other languages
English (en)
Inventor
Timmer Anjuli
Coronella Julia
Gymnopoulos Marco
newman Roland
Fujita Ryo
Blot Vincent
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BR112019005783A2 publication Critical patent/BR112019005783A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se, em certas modalidades, as composições compreendendo os agentes de ligação monoclonal que ligam-se, de uma maneira específica, ao domínio extracelular de cmet e usos dos mesmos.
BR112019005783A 2016-09-29 2017-09-28 agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos BR112019005783A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401428P 2016-09-29 2016-09-29
PCT/JP2017/035259 WO2018062402A1 (en) 2016-09-29 2017-09-28 Cmet monoclonal binding agents, drug conjugates thereof and uses thereof

Publications (1)

Publication Number Publication Date
BR112019005783A2 true BR112019005783A2 (pt) 2019-06-18

Family

ID=61762708

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005783A BR112019005783A2 (pt) 2016-09-29 2017-09-28 agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos

Country Status (16)

Country Link
US (1) US11299547B2 (pt)
EP (1) EP3519440A4 (pt)
JP (1) JP6942179B2 (pt)
KR (1) KR102443619B1 (pt)
CN (4) CN109983030B (pt)
AU (1) AU2017335062B2 (pt)
BR (1) BR112019005783A2 (pt)
CA (1) CA3036643C (pt)
IL (1) IL265645B2 (pt)
MX (1) MX2019003570A (pt)
PH (1) PH12019500677A1 (pt)
RU (1) RU2744914C2 (pt)
SA (1) SA519401424B1 (pt)
SG (1) SG11201901399YA (pt)
TW (1) TWI770065B (pt)
WO (1) WO2018062402A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774923A4 (en) * 2018-03-28 2021-12-29 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cmet monoclonal binding agents, and uses thereof
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
JP2020180110A (ja) * 2019-03-29 2020-11-05 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体を含む医薬組成物
CN111363042B (zh) * 2020-03-30 2022-02-11 中国人民解放军第四军医大学 一种高特异性抗小鼠cd226单克隆抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE514715T1 (de) * 2006-02-06 2011-07-15 Metheresis Translational Res Sa Monoklonaler anti-met-antikörper, fragmente und vektoren davon zur behandlung von tumoren und entsprechende produkte
AU2011203499B2 (en) * 2006-03-30 2013-01-31 Novartis Ag Compositions and methods of use for antibodies of c-Met
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EA201201273A1 (ru) 2010-03-10 2013-02-28 Генмаб А/С Моноклональные антитела к с-мет
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2014085821A2 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-met
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
EP3194444B1 (en) * 2014-09-16 2019-07-10 Symphogen A/S Anti-met antibodies and compositions
EP3237446B1 (en) * 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
WO2016149265A1 (en) 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anti-met antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR20190040071A (ko) 2019-04-16
US20190330354A1 (en) 2019-10-31
MX2019003570A (es) 2019-06-03
RU2019112419A3 (pt) 2020-10-30
JP2019537556A (ja) 2019-12-26
CN116731177A (zh) 2023-09-12
CN116903742A (zh) 2023-10-20
CN109983030B (zh) 2023-07-04
US11299547B2 (en) 2022-04-12
PH12019500677A1 (en) 2019-07-29
SA519401424B1 (ar) 2023-07-09
JP6942179B2 (ja) 2021-09-29
WO2018062402A1 (en) 2018-04-05
IL265645A (en) 2019-05-30
CN116769033A (zh) 2023-09-19
TWI770065B (zh) 2022-07-11
EP3519440A1 (en) 2019-08-07
TW201817446A (zh) 2018-05-16
WO2018062402A8 (en) 2019-02-21
EP3519440A4 (en) 2020-03-25
SG11201901399YA (en) 2019-03-28
IL265645B2 (en) 2024-05-01
KR102443619B1 (ko) 2022-09-14
RU2019112419A (ru) 2020-10-30
CA3036643A1 (en) 2018-04-05
RU2744914C2 (ru) 2021-03-17
AU2017335062B2 (en) 2020-08-06
CA3036643C (en) 2021-10-26
CN109983030A (zh) 2019-07-05
IL265645B1 (en) 2024-01-01
AU2017335062A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112019005030A2 (pt) inibidores da interação de menina-llm
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
BR112014019611A2 (pt) agentes de ligação mica
EA201690314A1 (ru) Анти-garp-белок и его применения
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
BR112013028908A2 (pt) anticorpos c-kit e usos dos mesmos
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112017011234A2 (pt) anticorpos contra receptor da barreira hematoencefálica e métodos de uso
BR112019005783A2 (pt) agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]